Bio4t2 is leveraging its
PrismCore and
Bio-Engine technologies to generate next-generation Bi-CAR-T for solid tumors. The additional specificity, recognizing two targets, expands the range of tumors that can be addressed and increases the number of patients that may benefit from infusion of Bi-CAR-T. At the same time, Bi-CAR-T helps to mitigate the emergence of tumors that may lose expression of one of the targeted antigens leading to relapse.
